Gastrointestinal Stromal Tumours of the Rectum – Evaluating the National Registry Data with Respect to its Use in Clinical Practice

Česká verzia

Authors: R. Svatoň ¹; Z. Kala ¹; P. Kysela ¹; V. Procházka ¹ ; M. Eid ² ; T. Andrašina ³ ; K. Poredská ⁴; J. Strenková ⁵; R. Chloupková ⁵; L. Kunovsky ^1,4
Published in the journal: Klin Onkol 2019; 32(2): 117-123
Category: Original Articles

Summary

Background:

Gastrointestinal stromal tumours (GIST) are rare malignant mesenchymal tumours with an incidence of 1 in 100,000. They represent only 5% of gastrointestinal tumours. The GISTs are mainly located in the stomach (60–70%) and in the rectum in < 5% of cases. In the case of localized, resectable tumours, the treatment is surgical resection. Depending on the size and localization of the tumour in the rectum, either a local excision, rectal resection with anastomosis, or abdominoperitoneal amputation with permanent stoma can be performed. In contrast to carcinomas, the metastasis of GISTs into lymph nodes is rare; therefore, from an oncological point of view, lymphadenectomy in the form of mesorectal excision is not required. Neoadjuvant treatment using tyrosine-kinase inhibitors (TKI) is recommended for tumours larger than 5 cm and in case of tumours infiltrating surrounding organs or sphincters in order to achieve complete resectability, less mutilating and continent procedure. In GISTs with a positive resection line, re-resection can be attempted. Adjuvant TKI therapy can be considered in cases of CD117 positivity and after resections of GISTs with medium and high-risk malignant behaviour. The TKI treatment is also indicated in cases of unresectable and metastatic GISTs.

Methods:

Data obtained from the GIST registry by the 1^st January 2017, when 10 centres in the Czech Republic were contributing to the registry, were analysed.

Results:

We analysed 1,095 patients out of which 45 (4.1%) had GIST localized in the rectum. The average age of the patients was 60 years. There were significantly more males (68.9%; p = 0.0007) and symptomatic patients (62.2%; p = 0.034). In total, 82% of the patients underwent surgery. Local excision was performed in 37.8%, resection of the rectum with anastomosis in 29.7%, and Miles operation in 29.7%. In the cohort, most tumours were 2–5 cm in size and almost half of the tumours presented a high risk of malignant behaviour. Systemic treatment was reported in 73% of patients. A complete remission was achieved in 80% of patients with GIST of the rectum. The median survival rate was 11.3 years and the 5-year survival rate is 90.6%.

Conclusion:

Despite the success of TKI treatment, the only potentially curative method of rectal GISTs is a surgical R0 resection. Given the relatively rare frequency of these tumours, proper diagnosis and treatment is demanding. Therefore, these patients should be preferably treated in specialised centres.

This work was supported by grant MH CZ – RVO (FNBr, 65269705).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 19. 12. 2018

Accepted: 2. 2. 2019

Keywords:

gastrointestinal stromal tumour (GIST) – Rectum – therapy – resection

Zdroje

1. Brabec P, Šufliarsky J, Linke Z et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma 2009; 56 (5): 459–464.

2. Kawanowa K, Sakuma Y, Sakurai S et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37 (12): 1527–1535. doi: 10.1016/j.humpath.2006.07.002.

3. Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438 (1): 1–12.

4. Sircar K, Hewlett BR, Huizinga JD et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23 (4): 377–389.

5. Nilsson B, Bümming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer 2005; 103 (4): 821–829. doi: 10.1002/cncr.20 862.

6. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23 (2): 70–83.

7. Jurečková A, Kocáková I, Vyzula R. Klinický registr GIST. Klin onkol 2012; 25 (2): 135–138.

8. Onkologickeregistry.cz. [online]. GIST: O projektu. Dostupné z: http: //gist.registry.cz/index.php.

9. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25 (13): 1753–1759. doi: 10.1200/JCO.2006.07.3049.

10. Rubin BP, Blanke CD, Demetri GD et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med 2010; 134 (2): 165–170. doi: 10.1043/1543-2165-134.2.165.

11. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004; 202 (4): 430–438. doi: 10.1002/path.1546.

12. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42 (8): 1093–1103. doi: 10.1016/j.ejca.2006.01.030.

13. Nahas CS, Nahas SC, Marques CF et al. Gastrointestinal stromal tumor of the rectum treated with neoadjuvant Imatinib followed by transanal endoscopic microsurgery. Arq Bras Cir Dig 2015; 28 (1): 87–89. doi: 10.1590/S0102-67202015000100022.

14. Liu H, Yan Z, Liao G et al. Treatment strategy of rectal gastrointestinalstromal tumor (GIST). J Surg Oncol 2014; 109 (7): 708–713. doi: 10.1002/jso.23562.

15. Kala Z, Procházka V, Grolich T et al. Moderní trendy v chirurgii kolorektálního karcinomu aneb co by měl onkolog vědět o práci chirurga. Onkologie 2017; 11 (2): 54–60.

16. Kunovský L, Kala Z, Svatoň R et al. Transanální minimalne invazivní resekce rekta s totalni mezorektalni excizí po endoskopické mukózní resekci. Gastroent Hepatol 2017; 71 (3): 208–214. doi: 10.14735/amgh2017208.

17. Hohenberger P, Ronellenfitsch U, Oladeji O et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97 (12): 1854–1859. doi: 10.1002/bjs.7222.

18. Grassi N, Cipolla C, Torcivia A et al. Gastrointestinal stromal tumour of the rectum: report of a case and review of literature. World J Gastroenterol 2008; 14 (8): 1302–1304.

19. Jakob J, Mussi C, Ronellenfitsch U et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol 2013; 20 (2): 586–592. doi: 10.1245/s10434-012-2647-1.

20. Fiore M, Palassini E, Fumagalli E et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 2009; 35 (7): 739–745. doi: 10.1016/j.ejso.2008.11.005.

21. Hasegawa J, Kanda T, Hirota S et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 2007; 12 (3): 212–217. doi: 10.1007/s10147-007-0657-y.

22. Casali PG, Abecassis N, Bauer S et al. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines fordiagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl 4): iv68–iv78. doi: 10.1093/annonc/mdy095.

23. Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin North Am 2009; 23 (1): 129–137. doi: 10.1016/j.hoc.2008.11.002.

24. Wu X, Jiang W, Zhang R et al. Clinicopathological analysis of 61 patients with rectal gastrointestinal stromal tumors. Zhonghua Wei Chang Wai Ke Za Zhi 2014; 17 (4): 335–339.

25. Shen C, Chen H, Yin R et al. Clinicopathologic, surgical characteristics and survival outcomes of rectal gastrointestinal stromal tumors. Neoplasma 2015; 62 (4): 610–617. doi: 10.4149/neo_2015_073.

26. Pai VD, Demenezes JL, Patil PS et al. Multimodality therapy of rectal gastrointestinal stromal tumors in the era of imatinib-an Indian series. J Gastrointest Oncol 2016; 7 (2): 262–268. doi: 10.3978/j.issn.2078-6891.2015.088.

27. Cavnar MJ, Wang L, Balachandran VP et al. Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: organ preservation and improved oncologic outcome. Ann Surg Oncol 2017; 24 (13): 3972–3980. doi: 10.1245/s10434-017-6087-9.